Menu Search
Equities

Terns Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
430:FRA

Terns Pharmaceuticals Inc

Actions
  • Price (EUR)31.60
  • Today's Change2.20 / 7.48%
  • Shares traded400.00
  • 1 Year change+608.52%
  • Beta-0.2718
Data delayed at least 15 minutes, as of Feb 06 2026 20:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

  • Revenue in USD (TTM)0.00
  • Net income in USD-94.44m
  • Incorporated2020
  • Employees59.00
  • Location
    Terns Pharmaceuticals Inc1065 East Hillsdale Blvd.Suite 100, Suite 100FOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 525-5535
  • Fax+1 (650) 275-4395
  • Websitehttps://ternspharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.